Table 3. Response rate and MRD after PSM... | American Society of Hematology

Table 3.

Response rate and MRD after PSM in R vs O group-treated patients

Response¹¹	R-DHAP (LyMa), n = 168	O-DHAP (LyMa-101), n = 84	χ²
ORR	152 (90.5%)	77 (91.7%)
PR	24 (14.9%)	26 (33.3%)∗
CR/uCR	65/63 (79.5%)	51 (65.4%)
Stable disease	6 (3.7%)	0
Progressive disease	3 (1.9%)	1 (1.3%)
Not performed	7	6
MRD†: BM	R-DHAP (LyMa), n = 93/152 responders	O-DHAP (LyMa-101), n = 65/77 responders
Negative	59 (63.4%)	54 (83.1%)	χ²‡, 0.007
Positive	16	2
PNQ	18	9
Not performed	59	12
MRD†: blood	R-DHAP (LyMa), n = 96/152 responders	O-DHAP (LyMa-101), n = 64/77 responders
Negative	70 (72.9%)	61 (95.3%)	χ²‡, <0.001
Positive	7	0
PNQ	19	3
Not performed	56	13

Response¹¹	R-DHAP (LyMa), n = 168	O-DHAP (LyMa-101), n = 84	χ²
ORR	152 (90.5%)	77 (91.7%)
PR	24 (14.9%)	26 (33.3%)∗
CR/uCR	65/63 (79.5%)	51 (65.4%)
Stable disease	6 (3.7%)	0
Progressive disease	3 (1.9%)	1 (1.3%)
Not performed	7	6
MRD†: BM	R-DHAP (LyMa), n = 93/152 responders	O-DHAP (LyMa-101), n = 65/77 responders
Negative	59 (63.4%)	54 (83.1%)	χ²‡, 0.007
Positive	16	2
PNQ	18	9
Not performed	59	12
MRD†: blood	R-DHAP (LyMa), n = 96/152 responders	O-DHAP (LyMa-101), n = 64/77 responders
Negative	70 (72.9%)	61 (95.3%)	χ²‡, <0.001
Positive	7	0
PNQ	19	3
Not performed	56	13

PNQ, positive not quantifiable.

∗

Including 10 scored as PR due to BM biopsies not being performed at EOI. Twenty-one of the 26 individuals showed positron emission tomography metabolic CR.

†

MRD assessed within responding patients (PR and CR).

‡

χ² between negative and other.

View Large

This Feature Is Available To Subscribers Only